The process of elimination of immature T cells in the thymus which react strongly with self-antigens.

Processes of T cell selection that occur in the thymus.

Processes of T cell selection that occur in extrathymic locations, often resulting T cells of distinct specificities from those selected in the thymus.

Interacting selectively with a low density lipoprotein receptor.

The process whereby a relatively unspecialized T cell acquires the specialized features of a Th1 cell.

The formation from simpler components of fractalkine, a chemokine involved in the control of the key regulatory mechanisms of cell trafficking at sites of inflammation. It exists as a secreted protein and in a membrane-bound form, and exhibits a novel C-X-X-X-C cysteine signature motif. The counterpart of human fractalkine is murine neurotactin; fractalkine is also referred to as CX3C membrane-anchored chemokine or ABCD-3 and has been renamed CX3CL1.

The process whereby a relatively unspecialized T cell acquires specialized features of a Th2 cell.

Any process that modulates the frequency, rate or extent of the formation from simpler components of fractalkine, a chemokine involved in the control of the key regulatory mechanisms of cell trafficking at sites of inflammation.

The process whereby a relatively unspecialized T cell acquires specialized features of a cytotoxic T cell.

positive regulation of fractalkine biosynthesis

positive regulation of neurotactin biosynthesis

Any process that activates or increases the rate, frequency or extent of the formation from simpler components of fractalkine, a chemokine involved in the control of the key regulatory mechanisms of cell trafficking at sites of inflammation.

The chemical reactions involving chemokines, any of a subgroup of cytokines which act primarily on hemopoietic cells in acute and inflammatory processes and other immunoregulatory functions.

The chemical reactions involving fractalkine, a chemokine involved in the control of the key regulatory mechanisms of cell trafficking at sites of inflammation. It exists as a secreted protein and in a membrane-bound form, and exhibits a novel C-X-X-X-C cysteine signature motif. The counterpart of human fractalkine is murine neurotactin; fractalkine is also referred to as CX3C membrane-anchored chemokine or ABCD-3 and has been renamed CX3CL1.